topic

292 Unleashing CAR-NK cells against solid tumors by disrupting TGF-β signaling in the tumor microenvironment
Min-Suk Oh, Minkoo Seo, SangWon Yoon, Mihue Jang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) 333; DOI: 10.1136/jitc-2023-SITC2023.0292
293 Development of a MUC16-specific CAR-T cell exhibiting potent antitumor activity for the treatment of patients with recurrent ovarian cancer
Nicole A Protheroe, Kelly DellaGrotte, Harini Kantamneni, Sumati Sundaram, Scott F Heller, Christina Ferren, Collin Walter, Prashant R Nambiar, Corinne Decker, Alison Crawford, Tina Chang Albershardt

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) 334; DOI: 10.1136/jitc-2023-SITC2023.0293
68 Automating a spatial profiling workflow to explore the effects of hypoxia in the tumor microenvironment in head and neck cancer
Jenifer Caldara, Sarah Church, Regan Baird, David Mason, Kyla Teplitz, James Mansfield, Kelly Hunter, Joana Campos, Jill Brooks

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) 78; DOI: 10.1136/jitc-2023-SITC2023.0068
1226 Surgery is a window of opportunity: biomaterial-assisted delivery of immunotherapy reduces local recurrence of soft tissue sarcoma
Ben C Wylie, Francois Rwandamuriye, Cameron Evans, Marck Norrett, Rachael M Zemek, Swaminatha Iyer, Joost Lesterhuis

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) 1353; DOI: 10.1136/jitc-2023-SITC2023.1226
1236 Outcomes and adverse events in cancer patients after diagnosis of immunotherapy-associated diabetes mellitus: a retrospective cohort study
Eva Duvalyan, Mark Anderson, Robert J Rushakoff, Zoe Quandt

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) 1363-1364; DOI: 10.1136/jitc-2023-SITC2023.1236
1402 A potent, CD8 T cell targeted IL-2 A-Kine with a broad therapeutic window induces antitumor immunity in syngeneic and humanized mouse tumor models
Lennart Zabeau, Anje Cauwels, Alexander Van Parys, Sylvie Taveirne, Jared E Lopes, Erik Depla, Niko Kley

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) 1560; DOI: 10.1136/jitc-2023-SITC2023.1402
482 Deciphering the heterogeneity of B-cell checkpoint inhibitors within tertiary lymphoid structures: Implications for lung cancer immunotherapy
Corinne Ramos, Adele Ponzoni, Amandine Gerstenberg, Victor Senechal, Melodie Boute

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) 541; DOI: 10.1136/jitc-2023-SITC2023.0482
Subject index
Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1727-A1731; DOI: 10.1136/jitc-2023-SITC2023.subjectindex
793 Combined administration of the dual A_2aR/A_2bR antagonist etrumadenant with a reduced chemotherapy regimen leads to enhanced tumor efficacy and survival
Sachie Marubayashi, Dana Piovesan, Ferdie Soriano, Gonzalo Barajas, Ruben Flores, Janine Kline, Matthew J Walters, Daniel DiRenzo

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A890; DOI: 10.1136/jitc-2023-SITC2023.0793
815 Combination with IL-15Rβγ superagonist, Nanrilkefusp alfa, enhances CAR T and BOXR T cell anti-tumor activity
Emily Kuiper, Kathleen Whiteman, Daniel Garafola, Pratirodh Koirala, Shannon Smith, Klara Danova, Ekaterina Simonova, Lenka Palova Jelinkova, Irena Adkins, Amy Jensen-Smith

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A913; DOI: 10.1136/jitc-2023-SITC2023.0815

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages